9.00
0.00
(0.00%)
At close: January 9 at 8:00:22 AM GMT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,203.00
1,203.00
638.00
2,569.00
1,791.00
Cost of Revenue
500.00
500.00
351.00
1,315.00
1,142.00
Gross Profit
703.00
703.00
287.00
1,254.00
649.00
Operating Expense
15,508.00
15,508.00
19,050.00
18,774.00
16,520.00
Operating Income
-14,805.00
-14,805.00
-18,763.00
-17,520.00
-15,871.00
Net Non Operating Interest Income Expense
204.00
204.00
161.00
-1,212.00
-491.00
Pretax Income
-14,412.00
-14,412.00
-19,372.00
-50,085.00
-16,271.00
Net Income Common Stockholders
-14,412.00
-14,412.00
-19,372.00
-50,085.00
-16,271.00
Diluted NI Available to Com Stockholders
-14,412.00
-14,412.00
-19,372.00
-50,085.00
-16,271.00
Basic EPS
-0.10
-0.07
-0.10
-0.63
-0.08
Diluted EPS
-0.10
-0.07
-0.10
-0.63
-0.08
Basic Average Shares
194,653.91
197,111.57
194,588.25
79,637.96
194,584.52
Diluted Average Shares
194,653.91
197,111.57
194,588.25
79,637.96
194,584.52
Total Operating Income as Reported
-14,805.00
-14,805.00
-18,763.00
-17,520.00
-15,871.00
Rent Expense Supplemental
189.00
189.00
132.00
129.00
132.00
Total Expenses
16,008.00
16,008.00
19,401.00
20,089.00
17,662.00
Net Income from Continuing & Discontinued Operation
-14,412.00
-14,412.00
-19,372.00
-50,085.00
-16,271.00
Normalized Income
-14,749.00
-14,749.00
-17,960.00
-18,553.00
-16,050.00
Interest Income
242.00
242.00
191.00
--
--
Interest Expense
38.00
38.00
30.00
1,212.00
491.00
Net Interest Income
204.00
204.00
161.00
-1,212.00
-491.00
EBIT
-14,374.00
-14,374.00
-19,342.00
-48,873.00
-15,780.00
EBITDA
-13,787.00
-13,787.00
-18,849.00
-48,359.00
-14,560.00
Reconciled Cost of Revenue
500.00
500.00
351.00
1,315.00
1,142.00
Reconciled Depreciation
587.00
587.00
493.00
514.00
1,220.00
Net Income from Continuing Operation Net Minority Interest
-14,412.00
-14,412.00
-19,372.00
-50,085.00
-16,271.00
Total Unusual Items Excluding Goodwill
337.00
337.00
-1,412.00
-31,532.00
-221.00
Total Unusual Items
337.00
337.00
-1,412.00
-31,532.00
-221.00
Normalized EBITDA
-14,124.00
-14,124.00
-17,437.00
-16,827.00
-14,339.00
12/31/2020 - 12/6/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SLNCF Silence Therapeutics plc
1.6350
0.00%
ROQ.L Roquefort Therapeutics plc
3.6500
-9.88%
OBD.L Oxford BioDynamics Plc
0.9110
-8.90%
GSTC GlobeStar Therapeutics Corporation
0.0004
+16.67%
OCC.AX Orthocell Limited
1.3550
-4.58%
SLN Silence Therapeutics plc
5.99
-5.52%
ITRM Iterum Therapeutics plc
1.6500
-8.33%
NNVC NanoViricides, Inc.
1.3500
-2.88%
CKPT Checkpoint Therapeutics, Inc.
3.1600
-1.56%
MESO Mesoblast Limited
17.18
0.00%